Research programme: RTP 801 siRNA therapeutics - Quark Pharmaceuticals/Pfizer

Drug Profile

Research programme: RTP 801 siRNA therapeutics - Quark Pharmaceuticals/Pfizer

Alternative Names: CTi-1; CTPi-1; QP-CO1; QP-LI1; QP-LI2; RNA interference based therapeutics

Latest Information Update: 16 Jul 2016

Price : $50

At a glance

  • Originator Quark Pharmaceuticals
  • Class Small interfering RNA
  • Mechanism of Action RNA interference; Small interfering RNA inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Chronic obstructive pulmonary disease
  • No development reported Acute lung injury; Respiration disorders

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Acute-lung-injury in USA
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Respiration-disorders in USA
  • 17 Nov 2015 Preclinical trials in Chronic obstructive pulmonary disease in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top